OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
November 29, 2023
KarXT (xanomeline-trospium) is currently in development to treat schizophrenia and psychosis related to Alzheimer disease.
Vivos becomes the first company to bring to market an alternative to continuous positive airway pressure (CPAP) or surgical neurostimulation implants for patients with severe OSA.
The CDC’s Morbidity and Mortality Weekly Report show pediatric influenza hospitalization rates returned to levels that preceded the COVID-19 pandemic.
The FDA will investigate all currently approved CAR T-cell treatments, as well as BCMA-directed and CD19-directed genetically modified autologous CAR T-cell therapies, for the risk of secondary T-cell malignancies.
A Q&A with Leslie Orne, CEO of Trinity Life Sciences, who discusses the latest developments in the life sciences industry and potential paths forward for companies in the space.
November 28, 2023
Law aims to mitigate ongoing global drug shortages.
Researchers highlight steps to be taken in the European Union to manage the challenge of ongoing drug shortages.
The launch of the Elecsys HBeAg quant immunoassay adds to Roche's viral hepatitis testing portfolio.
Ogsiveo is the first and only drug approved by the FDA to treat desmoid tumors.
For manufacturers who participate in the 340B program, costs have increased because they are required to provide steep discounts on their drugs at levels far below private market prices.